Suchergebnisse - "Brown, Jennifer R"

PubPharm (28)

1

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

enthalten in: Annals of hematology | 2024

von Merryman, R. | Redd, R. | Freedman, A. | +22

2

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Mato, A. | Woyach, J. | Brown, J. | +32

3

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia

enthalten in: Leukemia | 2023

von Ryan, C. | Brander, D. | Barr, P. | +15

4

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1) : results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

enthalten in: The Lancet. Haematology | 2022

von Bannerji, R. | Arnason, J. | Advani, R. | +16

CommentIn: Lancet Haematol. 2022 May;9(5):e314-e315. - PMID 35366964

5

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

enthalten in: Haematologica | 2022

von Allan, J. | Pinilla-Ibarz, J. | Gladstone, D. | +16

6

Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001) : analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study

enthalten in: The Lancet. Haematology | 2021

von Eyre, T. | Schuh, A. | Wierda, W. | +12

CommentIn: Lancet Haematol. 2021 Dec;8(12):e868-e870. - PMID 34735861

7

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

enthalten in: Investigational new drugs | 2021

von Danilov, A. | Spurgeon, S. | Siddiqi, T. | +4

8

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

enthalten in: Blood | 2021

von Byrd, J. | Woyach, J. | Furman, R. | +14

CommentIn: Blood. 2021 Jun 17;137(24):3313-3314. - PMID 34137848

9

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

enthalten in: Leukemia | 2021

von Davids, M. | Fisher, D. | Tyekucheva, S. | +9

10

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN) : a phase 1/2 study

enthalten in: Lancet (London, England) | 2021

von Mato, A. | Shah, N. | Jurczak, W. | +41

CommentIn: Lancet. 2021 Mar 6;397(10277):855-857. - PMID 33676615